Weight Loss Shots for $99/Month: How Telehealth Made GLP-1 Affordable
GLP-1 weight loss injections used to cost $900–$1,300/month without insurance. Telehealth compounding programs now make them available for $99–$125/month. Here is how the model works and how to access it.
Written by Trimi Medical Team. Medically reviewed by Dr. Amanda Foster, MD. This guide explains what GLP-1 weight loss injections are, how telehealth compounding programs make them affordable, and what to expect from treatment.
Quick links: Semaglutide $99/month, Tirzepatide $125/month, and get a prescription today.
More on Affordable Weight Loss Injections
Ozempic Alternative for $99/Month
Compounded semaglutide versus Ozempic — the full comparison.
Why Is Compounded Semaglutide So Cheap?
The economics behind $99 semaglutide.
Start Semaglutide This Week
Quick-start guide from signup to first injection.
Semaglutide Without a Doctor Visit
How telehealth prescriptions work.
The Weight Loss Injection Revolution — And Who Got Left Behind
GLP-1 receptor agonist injections have transformed the treatment of obesity. For decades, effective medical weight loss required either bariatric surgery — a significant operation with meaningful risks and recovery time — or medications with modest efficacy and significant side effects. The introduction of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) changed that calculus entirely.
Clinical trials documented weight loss that previous non-surgical interventions simply could not match: 15% with semaglutide, 22% with tirzepatide at the highest doses. These are numbers that were once associated only with surgical weight loss procedures. A once-weekly injection could deliver results that changed metabolic health, reduced cardiovascular risk, and improved quality of life for patients with obesity.
But the brand-name medications carrying these results were priced between $900 and $1,349 per month. Insurance coverage was (and remains) inconsistent and often unavailable. The patients who most needed effective weight loss treatment were frequently the same patients who could least afford $1,000 per month. A medical breakthrough that could benefit millions was effectively walled off by its price.
Telehealth compounding programs like Trimi exist to solve exactly this problem. By combining the efficiency of digital healthcare delivery with the economics of pharmaceutical compounding, they bring the same active molecules to patients at prices that are genuinely accessible: semaglutide at $99 per month, tirzepatide at $125 per month.
What Are GLP-1 Weight Loss Injections?
GLP-1 receptor agonists are a class of medications that mimic glucagon-like peptide-1, a hormone produced in the gut in response to food intake. GLP-1 signals to the brain's hypothalamus that sufficient food has been consumed — it is part of the natural satiety signaling system that tells you when you are full.
In their natural form, GLP-1 molecules are broken down quickly — they have a half-life of only a few minutes in the body. Pharmaceutical GLP-1 receptor agonists are engineered to last much longer. Semaglutide, for example, has a half-life of approximately one week — allowing a single weekly injection to maintain therapeutic blood levels continuously. This sustained receptor activation keeps appetite suppression consistently active rather than providing only the brief post-meal signal of natural GLP-1.
The effects are multiple: reduced appetite (patients describe thinking about food less, feeling full more quickly), slowed gastric emptying (food stays in the stomach longer, extending the feeling of fullness), reduced cravings, and for tirzepatide, additional metabolic effects through GIP receptor activation. Together, these effects create conditions in which significant caloric reduction is possible without the same level of hunger-driven discomfort that makes traditional diets so difficult to sustain.
How the $99/Month Model Works
Trimi's $99/month model for compounded semaglutide and $125/month for compounded tirzepatide is built on two pillars: telehealth efficiency and pharmaceutical compounding economics.
The telehealth model
Traditional weight management clinics charge for office visits, lab work, facility overhead, and in-person provider time. A single consultation at an obesity specialist can cost $200 to $400. Follow-up appointments add more. Administrative infrastructure — billing staff, intake staff, insurance navigation — adds overhead that is distributed across patients in the form of higher fees.
Trimi replaces in-person visits with asynchronous digital health assessments. A patient completes a structured questionnaire covering their medical history, medications, weight history, and goals. A physician reviews this information — typically a 10 to 15 minute time investment — and prescribes if appropriate. This is medically equivalent to an in-person consultation for this purpose, because the relevant clinical information is collected either way. But the cost is dramatically lower because no physical facility is required.
The compounding model
Brand-name GLP-1 medications include the cost of R&D, patent protection, FDA brand approval, marketing budgets, auto-injector device engineering, and multi-layer supply chain markup. Compounded versions contain the same active molecule, prepared by an accredited pharmacy from pharmaceutical-grade API, with none of those cost layers. The result is the same clinical benefit at a fraction of the price.
For a detailed breakdown of every cost layer that compounding eliminates, see our guide to why compounded semaglutide is so much cheaper than Ozempic.
Semaglutide vs Tirzepatide: Which Weight Loss Shot?
Trimi offers two options: compounded semaglutide at $99/month and compounded tirzepatide at $125/month. Both are effective GLP-1 receptor agonists; tirzepatide adds GIP receptor activation for greater weight loss in most patients. Here is a practical comparison:
| Feature | Semaglutide ($99/mo) | Tirzepatide ($125/mo) |
|---|---|---|
| Brand-name equivalents | Ozempic, Wegovy | Mounjaro, Zepbound |
| Mechanism | GLP-1 receptor agonist | Dual GIP + GLP-1 receptor agonist |
| Average weight loss (trials) | ~14.9% (STEP 1) | ~22.5% at max dose (SURMOUNT-1) |
| Injection schedule | Once weekly | Once weekly |
| Starting dose | 0.25mg/week | 2.5mg/week |
| Max dose | 2.4mg/week | 15mg/week |
| Monthly cost at Trimi | $99/month | $125/month |
| Best for | First-line GLP-1, semaglutide responders | Maximum weight loss, type 2 diabetes |
Your Trimi provider helps you choose based on your medical history, prior GLP-1 experience, and weight loss goals. If you are new to GLP-1 medications, semaglutide is often the recommended starting point given its long clinical track record and the $26/month lower cost. If you have type 2 diabetes, have tried semaglutide before, or want to maximize weight loss potential, tirzepatide may be the better option.
What the Injection Actually Involves
Many people considering weight loss injections for the first time are concerned about the self-injection aspect. Here is what the process actually looks like:
Frequency
Once per week, same day each week. Most patients pick a day that is easy to remember — Sunday morning, Friday evening, whatever fits their routine.
Injection sites
Subcutaneous (just under the skin, not intramuscular) injection in the abdomen (2+ inches from navel), outer thigh, or upper arm. Rotate sites with each injection.
Needle size
A standard 31-gauge insulin syringe is used — the needle is very fine and short (typically 4 to 6mm). Most patients describe minimal discomfort, less than a finger-stick glucose test.
Volume injected
Varies by dose. A typical 0.5mg semaglutide dose is approximately 0.1ml — a very small volume. The injection takes seconds.
Storage
Refrigerate between uses. Do not freeze. Use within the labeled beyond-use date.
Total time per week
Under two minutes from prep to disposal, including swabbing the site, drawing the dose, injecting, and disposing of the syringe.
For detailed injection instructions and a step-by-step walkthrough, see our quick-start guide to getting your first dose. Your first Trimi shipment also includes written injection instructions and access to your provider for questions.
Managing Side Effects
The most common side effects of GLP-1 weight loss injections are gastrointestinal: nausea, constipation, and occasionally diarrhea. These effects are more pronounced during dose escalation and typically diminish significantly within four to eight weeks at each new dose level. Several strategies help manage them:
Eat smaller portions
Your appetite will be suppressed — honor it. Eating past fullness is a primary trigger for nausea.
Eat slowly
The slower gastric emptying means food should be consumed more slowly. Rushing meals triggers nausea more than taking your time.
Avoid high-fat foods early on
Fatty foods slow gastric emptying further. During dose escalation, lighter meals reduce GI discomfort.
Stay hydrated
Constipation is the most common GI side effect with tirzepatide specifically. Adequate water intake and dietary fiber are the primary management tools.
Inject in the evening
Some patients find injecting in the evening means any nausea coincides with sleep rather than daytime activities.
Contact your provider if needed
Your Trimi subscription includes provider access. If side effects are significantly interfering with daily life, contact your provider — the dose escalation schedule can be slowed.
Who Is Getting $99 Weight Loss Injections?
The patients accessing compounded GLP-1 injections through telehealth platforms like Trimi reflect the broad group priced out of brand-name options:
- Patients who were on Ozempic or Wegovy with insurance coverage that was denied, discontinued, or became unaffordable after a plan change
- Uninsured adults who have clinically significant obesity and cannot access brand-name medications at retail prices
- Medicare beneficiaries whose Part D plan does not cover obesity medications (currently required by law to exclude them)
- Self-employed individuals on high-deductible health plans where weight loss medications are not covered
- Patients who want to try GLP-1 therapy before committing to the cost of brand-name options
- People who responded well to semaglutide trials or samples and are looking for a sustainable long-term cost
The clinical eligibility criteria are the same regardless of which channel patients access — BMI 30 or higher, or 27 or higher with a qualifying comorbidity. The difference is entirely financial access. For more information on eligibility, see our GLP-1 candidate eligibility guide.
Frequently Asked Questions
What is a weight loss shot and how does it work?
Weight loss shots — formally called GLP-1 receptor agonist injections — are weekly subcutaneous (under-the-skin) injections of either semaglutide or tirzepatide. These medications mimic a gut hormone called GLP-1 that naturally signals fullness after eating. When present at therapeutic levels, they significantly reduce appetite, slow gastric emptying, and support sustained caloric reduction without the same hunger and cravings that plague traditional diets. Clinical trials have shown 14 to 22 percent body weight loss over 16 to 18 months.
How can weight loss shots cost only $99/month?
The $99 price is possible because Trimi's model uses compounded semaglutide — the same active molecule as Ozempic and Wegovy, prepared by an accredited compounding pharmacy rather than a brand-name manufacturer. Compounding eliminates the pharmaceutical supply chain markups, patent premiums, branded device costs, and marketing budgets that drive brand-name prices to $900 to $1,349 per month. The molecule is identical; the infrastructure around it is dramatically leaner.
What is the difference between a $99 weight loss shot and a $1,000 one?
The active ingredient — semaglutide — is the same molecule at equivalent doses. The differences are commercial: delivery device (auto-injector pen versus vial and syringe), manufacturer (Novo Nordisk versus accredited compounding pharmacy), and distribution channel (traditional pharmacy versus direct-to-patient telehealth). These commercial differences account for almost the entire price gap. The clinical weight loss mechanism, expected outcomes, and side effect profile are the same.
Do I need to see a doctor in person to get a weight loss shot?
No. Through Trimi, the entire process is online. You complete a health assessment, a board-certified physician reviews it and prescribes if appropriate, and your medication ships directly to your home. You never need to visit a clinic, wait in a waiting room, or schedule an in-person appointment. Ongoing provider access for dose adjustments and questions is also available online.
Am I a good candidate for weight loss injections?
Standard clinical criteria for GLP-1 weight loss therapy are a BMI of 30 or higher (obesity), or a BMI of 27 or higher with a weight-related health condition such as prediabetes, hypertension, or high cholesterol. If you have struggled with weight loss through diet and exercise alone, have no contraindications to semaglutide or tirzepatide, and are not pregnant, you may well be a good candidate. Trimi's online health assessment and physician review will confirm eligibility.
How long does it take to see results from weight loss shots?
Most patients notice appetite suppression — reduced hunger, earlier satiety — within the first one to two weeks. Measurable weight loss typically appears within four to six weeks. Significant results, often 5 to 10 percent of body weight, are commonly seen by months three to four. The full therapeutic effect develops over six to twelve months as the dose reaches maintenance levels. The STEP 1 trial for semaglutide showed average 14.9% body weight loss at 68 weeks.
What happens if I stop taking weight loss shots?
Most patients experience gradual weight regain after discontinuing GLP-1 medications because the medication was managing the biological drivers of appetite — and those return when the medication stops. This reflects the chronic, relapsing nature of obesity as a condition. Clinical trials including STEP 4 for semaglutide and SURMOUNT-4 for tirzepatide consistently show significant weight regain within 12 months of stopping. Most guidelines now recommend treating obesity as a chronic condition requiring long-term management.
Sources & References
- Wilding JPH et al. STEP 1: Once-weekly semaglutide for weight management. NEJM, 2021.
- Jastreboff AM et al. SURMOUNT-1: Tirzepatide for obesity. NEJM, 2022.
- Ryan DH et al. STEP 3: Semaglutide with intensive behavioral intervention. NEJM, 2021.
- FDA: Compounding and FDA — Questions and Answers.
- NABP PCAB compounding pharmacy accreditation standards.
- NIDDK: Prescription medications for overweight and obesity.
- Wegovy FDA prescribing information, 2023.
- Zepbound FDA prescribing information, 2023.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or weight loss program. Individual results vary. Trimi provides compounded GLP-1 medications through licensed telehealth physicians.